A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

Phase 2 Completed 56 enrolled Arog Pharmaceuticals, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This pilot Phase II study is designed to evaluate the efficacy and tolerability of crenolanib in two cohorts of AML patients with FLT3 activation mutations (patients whose leukemia has recurred after prior chemotherapy not including a FLT3 TKI and patients whose leukemia has progressed after prior therapy with a FLT3 TKI).

Timeline

Start: 2012-10
Primary completion: 2019-04
Completion: 2019-04

Publications

Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, Levis M. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood. 2014 Jan 2;123(1):94-100. doi: 10.1182/blood-2013-10-529313. Epub 2013 Nov 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Crenolanib	Small molecule	100 mg	Oral

A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

Summary

Timeline

Publications

Drugs

Indications